Sartorius Stedim Biotech (Sartorius Stedim Biotech) Interest Expense : $-138 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sartorius Stedim Biotech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sartorius Stedim Biotech's interest expense for the three months ended in Dec. 2023 was $ -43 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-138 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sartorius Stedim Biotech's Operating Income for the three months ended in Dec. 2023 was $ 138 Mil. Sartorius Stedim Biotech's Interest Expense for the three months ended in Dec. 2023 was $ -43 Mil. Sartorius Stedim Biotech's Interest Coverage for the quarter that ended in Dec. 2023 was 3.24. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sartorius Stedim Biotech Interest Expense Historical Data

The historical data trend for Sartorius Stedim Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Interest Expense Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-5.12

-8.30

-11.75

-19.70

-127.59

Sartorius Stedim Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															27.54	-21.84	-29.04	-44.18	-42.64

Sartorius Stedim Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-138 Mil.

Sartorius Stedim Biotech (OTCPK:SDMHF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sartorius Stedim Biotech's Interest Expense for the three months ended in Dec. 2023 was $-43 Mil. Its Operating Income for the three months ended in Dec. 2023 was $138 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $3,929 Mil.

Sartorius Stedim Biotech's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	138.277	/	-42.639
	=	3.24

The higher the ratio, the stronger the company's financial strength is.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SRTOY:USA DIM:Mexico DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.